ArticleInfection and drug resistance2025
Impact of Acid Suppressants on the Development of
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The comparative effectiveness and potential impact of individual proton pump inhibitors (PPIs) on the development of Methods: We retrospectively analyzed the data of 3287 patients tested for CDI at Mie University Hospital between January 2014 and June 2024, excluding 1917 patients who had received antibiotics within the prior 3 months. The PPIs studied included esomeprazole, omeprazole, rabeprazole, and lansoprazole. Results: Univariate logistic regression analysis revealed age and esomeprazole use as potential risk factors for CDI ( Conclusion: Our findings suggest that esomeprazole use and advanced age may increase the risk of CDI. Additionally, probiotics may help prevent CDI during PPI therapy. Selecting PPIs based on individual bleeding profiles and considering probiotics could be beneficial to mitigate the risk of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.